(Reuters) - Arena Pharmaceuticals Inc said Japanese drugmaker Eisai Co Ltd will market its diet drug in most markets worldwide as part of an expanded agreement, under which the companies will also develop the drug for other indications. Arena shares were up 5 percent in extended trading after closing at $4.08 on the Nasdaq on Thursday. Eisai already holds marketing rights to the drug, Belviq, in most in North and South America. Arena will also receive, based on certain conditions, up to about 35 percent of Eisai's net sales on the drug, which last year became the first new diet pill to be approved by U.S. health regulators in 13 years. via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment